447 filings
8-K
AKTX
Akari Therapeutics Plc
16 May 24
Akari Therapeutics Reports First Quarter
8:05am
10-Q
2024 Q1
AKTX
Akari Therapeutics Plc
Quarterly report
15 May 24
4:47pm
8-K
AKTX
Akari Therapeutics Plc
7 May 24
Cost Associated with Exit or Disposal Activities
5:05pm
425
AKTX
Akari Therapeutics Plc
1 May 24
Business combination disclosure
5:27pm
8-K
AKTX
Akari Therapeutics Plc
1 May 24
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
5:04pm
8-K
xcizbl vb53x9w4ug9
11 Apr 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6:30am
8-K
r8abmo7j n2s9i
1 Apr 24
Akari Therapeutics Reports Full-Year
6:30am
425
dko 269ecks4huis
11 Mar 24
Business combination disclosure
5:25pm
8-K
y0d4wb36f k2
11 Mar 24
Entry into a Material Definitive Agreement
5:24pm
425
97z0aruq4awkb7a
5 Mar 24
Business combination disclosure
4:57pm
425
tahlqffd641um3n5
5 Mar 24
Business combination disclosure
8:34am
8-K
s0h1dsc1w1dzb1tp
5 Mar 24
Entry into a Material Definitive Agreement
8:28am
D
xsc 0zp7zuyki00
9 Jan 24
$2.00 mm in equity / securities to be acquired, sold $2.00 mm, 2 investors
5:25pm
8-K
u0rqyu9
2 Jan 24
Akari Therapeutics Announces Existing Investors Support the Company
4:30pm
6-K
xdvw1 8mq5
1 Dec 23
Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors
8:00am
6-K
die7at
16 Nov 23
Current report (foreign)
8:00am
424B3
dz5r8nx6uoo0e9n8 e2
27 Oct 23
Prospectus supplement
4:15pm
EFFECT
uu3ovl kj05ssjy9nbe
27 Oct 23
Notice of effectiveness
12:15am
CORRESP
810o3
25 Oct 23
Correspondence with SEC
12:00am